СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia
☏ +381 11 4092 776, Fax: +381 11 3348 653
E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted* **ISSN Online 2406-0895**

Current topic / Актуелна тема

Jelena Dimitrijević[1,♣], Snežana Bošnjak[1], Ana Vidović[2,3], Marina Nikitović[1,2]

Comprehensive evaluation of risk factors for the development and complications of chemotherapy-induced febrile neutropenia

Свеобухватна процена фактора ризика за развој и компликације фебрилне неутропеније изазване хемиотерапијом

[1]Institute for Oncology and Radiology of Serbia, Belgrade, Serbia;
[2]University of Belgrade, Faculty of Medicine, Belgrade, Serbia;
[3]University Clinical Centre of Serbia, Clinic of Hematology, Belgrade, Serbia

Received: November 9, 2021
Revised: May 23, 2022
Accepted: May 31, 2022
Online First: June 7, 2022
DOI: https://doi.org/10.2298/SARH211109054D

*__Accepted papers__ are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

♣**Correspondence to:**
Jelena DIMITRIJEVIĆ
Institute for Oncology and Radiology of Serbia Pasterova 14, 11000 Belgrade, Serbia
E mail: **drjelenadimitrijevic@gmail.com**

Comprehensive evaluation of risk factors for the development and complications of chemotherapy-induced febrile neutropenia

Свеобухватна процена фактора ризика за развој и компликације фебрилне неутропеније изазване хемиотерапијом

SUMMARY

Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complications and death as well as delays in treatment, chemotherapy dose reductions, compromised treatment efficacy and reduced survival. The assessment of the patient-related risk factors plays a significant role in the prevention of febrile neutropenia and its complications. In the case of intermediate-risk chemotherapy, the patient-related factors contribute to the estimation of an overall febrile neutropenia risk as well as to timely planning of primary prophylaxis using growth factors. Patients presenting with febrile neutropenia undergo a detailed initial risk assessment for serious complications so that an appropriate treatment can be selected. Recommendations given by the guidelines outline the classification of and risk factors for febrile neutropenia complications. The usage of patient-related factors and validated tools for the risk assessment of complications makes it possible to optimize the treatment for each patient and to reduce the risk of morbidity and mortality due to FN.

Keywords: febrile neutropenia; patient-related risk factors; risk assessment

САЖЕТАК

Фебрилна неутропенија је озбиљно нежељено дејство хемиотерапије. Фебрилна неутропенија може довести до појаве компликација и смрти као и до кашњења у примени хемиотерапије, до смањења доза антинеопластичних лекова што може утицати на ефикасност онколошког лечења и скраћење преживљавања. Процена фактора ризика порекла пацијента игра значајну улогу у превенцији фебрилне неутропеније и њених компликација. У случају хемиотерапије умерене мијелоспуресивности, фактори порекла пацијента морају да се узму у обзир јер повећавају укупан ризик за фебрилну неутропенију. Адекватна процена укупног ризика за фебрилну неутропенију омогућава правовремено планирање примарне профилаксе применом фактора раста. Код пацијената који развију фебрилну неутропенију детаљно се процењује ризик од озбиљних компликација укључујући ту и смртни исход како би се одредио одговарајући приступ у лечењу. У водичима су дате препоруке за процену ризика за компликације на терену фебрилне неутропеније. Коришћењем валидираних помагала за процену компликација и адекватном проценом фактора ризика порекла пацијента могуће је прилагодити лечење фебрилне неутропеније сваком пацијенту и смањити ризик од компликација и смрти.

Кључне речи: фебрилна неутропенија; фактори ризика порекла пацијента; процена ризика

INTRODUCTION

Febrile neutropenia (FN) is an oncology emergency and one of the most frequent and most serious complications of chemotherapy treatment [1]. It is a significant cause of morbidity, mortality and burden to healthcare services [2]. The incidence of FN in patients receiving chemotherapy for solid tumors is 10 – 50 % while for hematological malignancies it is up to 80% [1,3]. Around 20 – 30 % patients with FN will present with complications requiring hospitalization with an overall mortality of 10 % [1].

FN is defined as a fever (oral temperature of >38.3°C or two consecutive readings of >38.0°C, 1 h apart)in patients with severe neutropenia (absolute neutrophil count of <0.5 × 10^9/l, or expected to fall below 0.5 × 10^9/l)[1,3,4]. In the majority of patients with FN, symptoms and signs of infection are absent. Bacteriaemia is documented in 20% of FN patients [1]. In the past, there used to be a prevalence of Gram(G)-negative bacteriaemia among patients with FN, but in the last few decades the shift has occurred towards G-positive bacteriaemia and at the present time the ratio between G-positive and G-negative bacteria is 60:40 [5]. Patients with FN and proven bacteriaemia have a worse prognosis with a mortality rate of 18% (G-negative) and 5% (G-positive) [1]. The most common isolated G-positive bacteria are: *Staphylococcus spp.,* enterococci, and viridans streptococci while among G-negative bacteria the most common are: *Escherichia coli, Klebsiella spp.* and *Pseudomonas aeuruginosa* [5]. Fungal and viral infections in patients with FN are rarely an initial type of infection and are related to prolonged severe neutropenia induced with high-dose chemotherapy regimens such as in haemathological malignancies.

RISK FACTORS FOR THE DEVELOPMENT OF FEBRILE NEUTROPENIA

There is a clear relationship between the severity of neutropenia and the dose-intensity of chemotherapy [1]. According to the risk to induce FN, all chemotherapy regimens are classified as high risk (incidence of FN >20%), intermediate risk (incidence of FN of 10%–20%) or low risk ones (incidence of FN <10%). The majority of high-risk regimens are high-dose chemotherapy regimens for the treatment of lymphomas, leukemias, osteo- and soft tissue sarcomas and certain regimens for the treatment of colorectal, pancreatic, and breast cancer [6].

It has been shown that several factors, other than chemotherapy itself, are responsible for increasing the risk of FN and its complications which is of special importance in the case of intermediate risk chemotherapy regimens. These patient-related factors augment the risk produced by chemotherapy and create an overall risk for developing FN. The overall FN risk is high if one or more patient-related factors are present. In everyday clinical practice, the majority of standard-dose chemotherapy protocols with the intermediate risk for FN are used for the treatment of various types of solid tumors [6]. Assessment of patient-related factors is of importance in order to prevent occurrence of FN and, consequently, morbidity, mortality,

and burden to health care services. On the other hand, assessment of patient-related factors in order to prevent FN results in better prevention of chemotherapy dose delays and dose reductions that may affect overall survival.

Several meta-analyses have shown that primary prophylaxis with the granulocyte colony-stimulating factor (G-CSF) reduces the risk of FN by at least 50% in patients with solid tumors and lymphomas as well as early mortality during chemotherapy and infection-induced mortality. [7–9]. Most guidelines recommend the use of the G-CSF prophylactically if the risk of FN is >20% for all planned cycles of treatment [1,3,6]. For patients with an intermediate risk, it is important to consider patient-related factors, as already mentioned (Figure 1) [1,3,6]. With most chemotherapy used for the treatment of common malignancies; the risk of FN is maximal during the first course of chemotherapy [4]. Thus, for patients at risk, primary prophylaxis of FN is recommended from the first cycle of therapy.

Data from the guidelines regarding patient-related risk factors are heterogenous (Table 1) [1,3,6].

Patient age is one of the most important patient-related risk factors for FN and the only one that all the guidelines agree upon. Advanced disease, comorbidities, poor performance status as well as nutritional status are equally important. The presence of malnutrition increases treatment-related toxicities in cancer patients receiving chemotherapy [10]. It is estimated that in 10–20% of patients, death si caused by malnutrition-related adverse events and not by the tumor itself; therefore, early assessment for malnutrition and adequate nutritional intervenitons before the start of the treatment are recommended [10]. Before the diagnosis of malnutrition is considered, it is mandatory to assess patients for being “at risk” of malnutrition by any validated risk screening tool (e.g. Malnutrition Universal Screening Tool, MUST) [11].There are several criteria that should be addressed in order to diagnoze malnutrition: weight loss, anorexia, body composition (e.g. fat-free mass index, FFMI), anthropometry (e.g. body-mass index, BMI), and biochemical markers (albumin levels, C-reactive protein levels). The proposed criteria for the diagnosis of malnutrition are: unintentional weight loss > 10% indefinite of time, or>5% over the last 3 months combined with either BMI <20 kg/m2 (<70 years), or <22 kg/m2 (≥70 years), or FFMI <15 and 17 kg/m2 in women and men, respectively [11].

In general, careful assessment of patient-related risk factors in patients scheduled to receive chemotherapy of intermediate risk for FN enables adequate estimation of an overall FN risk and, consequently, timely planning of primary prophylaxis with the G-CSF in order to prevent FN and its complications.

RISK FACTORS FOR THE COMPLICATIONS OF FEBRILE NEUTROPENIA

As mentioned before, FN is one of the most serious complications of chemotherapy treatment. However, not all the patients with FN will have complications or require hospitalizations. For example, a worse prognosis is expected in high-risk FN with the case of proven bacteriaemia or the presence of a focal site of presumed infection (e.g. pneumonia, cellulitis) [1].

Multiple randomized control trials have demonstrated that outpatinet treatment is safe and feasible in patients with low-risk FN, with associated savings in resources and improved patient's quality of life [12].

Considering that the rate of complications from FN is still high, it is crucial to accurately stratify patients who can safely be treated on an outpatient basis. Several tools have been proposed in order to recognize patients with high-risk FN. One of the most common used tools for risk stratification is the Multinational Association for Supportive Care in Cancer (MASCC) tool (Table 2) [13].

An MASCC score of 21 or more identifies low-risk patients eligible for outpatient care with a positive predictive value of 91%, a specificity of 68%, and a sensitivity of 71% [12]. Another commonly used risk stratification tool is the Clinical Index of Stable Febrile Neutropenia (CISNE) score (Table 3) [13].

It was validated to predict major complications in FN patients who are asigned a score ≥3 (high risk). Due to the validation study design, the CISNE can only be applied to patients with solid tumors treated with standard-dose chemotherapy) [13].

Although these scores are validated and no-time consuming tools for the prediction of complications in FN patients, it is not clear whether they could be applied to all FN patients. In a recent paper published in the Journal of Oncology Practice, the authors deem that one tool cannot fit all the patients with FN [14]. In this paper, it is stated that the treatment of FN should be personalized and that several patient-related, treatment-related and logistic factors shoul be taken into account in order to decide whether to treat the FN patient as an inpatient or as an outpatient. It is discussed that an ideal tool to help decision making in this regard probably should be a system that accommodates all components of patient care and patient-related factors: type of cancer, expected prognosis, intent of cancer treatment and type of chemotherapy regimen, expected severity and duration of neutropenia, patient's comorbidities, patient's performance status, hemodynamic stability, adherence to oral antibiotics, patient's compliance to close monitoring, and availability of emergency health care sevices. Once again, the focus is on the patient-related factors.

The current ASCO and Infectious Diseases Society of America (IDSA) guideline reccomends the use of MASCC score and clinical criteria to identify patients with high-risk FN [3]. In the ASCO guideline, Taplitz et al. based clinical criteria on various patient-specific and organ-specific symptoms, signs and conditions [3]. Patients with an MASCC score < 21 and the presence of clinical criteria are candidates for inpatient treatment. In the case of an MASCC score ≥21 and the absence of clinical criteria, patients with FN should be treated as outpatients. This guideline also recommends the use of the CISNE score in the case of clinically stable low-risk FN patients with solid tumors treated with mild-to moderate-intensity chemotherapy, as already mentioned before [3]. The current ESMO guideline recommends the use of the MASCC score to identify low-risk and high-risk FN patients [1]. The current NCCN guideline recommends the use of these tools (MASCC or CISNE) together with several additional patient-related factors (Figure 2) [4].

CONCLUSION

Chemotherapy-induced FN may lead to serious complications and represents a burden to healthcare services. A careful and comprehensive assessment of risks for FN development and its complications plays a key role in determining whether the G-CSF should be initiated for

primary prophylaxis or not. In the case of developed FN, it is crucial to perform a careful risk assessment for complications with validated tools to determine whether the FN management should be inpatient or outpatient. Besides the validated tools, the gudelines suggest the use of clinical criteria in order to make a treatment of FN more personalized and to reduce the incidence of its complications including death.

ACKNOWLEDGMENT

The authors declare that the article was written according to ethical standards of the Serbian Archives of Medicine as well as ethical standards of medical facilities for each author involved.

Conflict of interest: None declared.

REFERENCES

1. J. Klastersky J, De Naurois, K. Rolston, B. Rapoport, G. Maschmeyer, M. Aapro, J. Herrstedt. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27 (5): v111-v118. doi: 10.1093/annonc/mdw325. PMID: 27664247.
2. Wang W, Li E, Campbell K, McBride A, D'Amato S. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. JCO Oncol Pract 2021;17(8):e1139-e1149. doi: 10.1200/OP.20.00994. PMID: 33961490.
3. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 2018; 36 (14): 1443-1453. doi: 10.1200/JCO.2017.77.6211. PMID: 29461916.
4. National Comprehensive Cancer Network. (2021). Prevention and Treatment of Cancer Related Infections (version1.2021). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.
5. Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, et al. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ Open 2019;9: e025744. doi:10.1136/bmjopen-2018-025744. PMID: 31129580.
6. National Comprehensive Cancer Network. (2022). Hematopietic Growth Factors (version 1.2022). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. 7.
7. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23(18):4198-214. doi: 10.1200/JCO.2005.05.645. PMID: 15961767.
8. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11:404. doi: 10.1186/1471-2407-11-404. PMID: 21943360.
9. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25(21):3158-67. doi: 10.1200/JCO.2006.08.8823. PMID: 17634496.11.
10. Muscartioli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Berts H et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 2021; 40:2898-2913. doi: 10.1016/j.clnu.2021.02.005. PMID: 33946039.
11. Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition e A consensus report from the global clinical nutrition community. J Parenter Enteral Nutr 2019; 43(1):32-40. doi: 10.1002/jpen.1440. PMID: 30175461.
12. Kubeček O, Paterová P, Novosadová M. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life (Basel) 2021;11(12):1387. doi: 10.3390/life11121387. PMID: 34947918.
13. Zheng B, Toarta C, Cheng W, Taljaard M, Reaume N, Perry JJ. Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020; 149:102922. doi: 10.1016/j.critrevonc.2020.102922. PMID: 32244162.
14. Wijeratne DT, Wright K, Gyawali B. Risk-Stratifying Treatment Strategies for Febrile Neutropenia-Tools, Tools Everywhere, and Not a Single One That Works? JCO Oncol Pract 2021; 17(11):651-654. doi: 10.1200/OP.21.00148. PMID: 33914611.



Figure 1. Decision making algorithm regarding the usage of the G-CSF in primary prophylaxis of FN;

FN – febrile neutropenia; G-CSF – granulocyte colony-stimulating factor

Table 1. Patient-related factors considered by the guidelines as risk factors for febrile neutropenia

NCCN	ASCO	ESMO
Prior ChT or RT Persistent neutropenia Bone marrow involvement by tumor Recent surgery and/or open wounds Liver disfunction (bilirubin > 2.0) Renal disfunction (creatinine clearance < 50) Age > 65 years receiving full dose chemotherapy	Age > 65 years ECOG performance status Nutritional status Comorbidities History of prior FN	Age Advanced disease History of prior FN; No antibiotic prophylaxis or G-CSF use Mucositis Poor performance status Cardiovascular disease

NCCN – National Comprehensive Cancer Network; ASCO – American Society of Clinical Oncology; ESMO – European Society for Medical Oncology; ChT – chemotherapy; RT – radiotherapy; ECOG – Eastern Cooperative Oncology Group; G-CSF – granulocyte colony-stimulating factor; FN – febrile neutropenia

Table 2. Multinational Association for Supportive Care in Cancer tool for risk stratification in febrile neutropenia

Burden of illness	Severe symptoms Moderate symptoms No or mild symptoms	0 3 5
No hypotension (systolic blood pressure > 90 mmHg)		5
No chronic obstructive pulmonary disease		4
Solid tumor or hematological malignancy with no previous fungal infection		4
No dehydration requiring parenteral fluids		3
Outpatient at presentation		3
Age < 60 years		2

Table 3. Clinical Index of Stable Febrile Neutropenia score for risk stratification in febrile neutropenia

ECOG performance status ≥ 2	2
Stress-induced hyperglycemia ≥ 6.7 mmol/L or ≥ 13.9 mmol/L in diabetics or if on steroids	2
Chronic obstructive pulmonary disease	1
Cardiovascular disease	1
NCI mucositis ≥ 2	1
Monocytes < 200/μl	1

ECOG – Eastern Cooperative Oncology Group; NCI – National Cancer Institute



Figure 2. NCCN initial risk assessment algorithm for FN patients;

ECOG – Eastern Cooperative Oncology Group; MASCC – Multinational Association for Supportive Care in Cancer; CISNE – Clinical Index of Stable Febrile Neutropenia

